Identifying clopidogrel resistance during chronic therapy: The case for a biochemical approach

• References

• 1 Wenaweser P, Dorffler-Melly J, Imboden K. et al. Stent thrombosis is associated with an impaired respose to antiplatelet therapy. J Am Coll Cardiol 2005; 45: 1748-1752.
• 2 Chirkov YY, Chirkova LP, Sage RE. et al. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclic AMP-elevating effects of prostaglandin E1. J Cardiovasc Pharmacol 1995; 25: 961-966.
• 3 Fontana P, Senouf D, Mach F. Biologic effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008; 121: 463-468.
• 4 Schafer A, Weinberger S, Flierl U. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y₁₂-specific assay. Thromb Haemost 2008; 100: 618-625.
• 5 Bonello L, Camoin-Jau L, Arques S. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation indexdecrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.